RQ-00433412

RQ-00433412 is a novel, small molecule ghrelin receptor agonist discovered and developed by RaQualia Pharma. The compound is designed to target the ghrelin receptor, which plays a central role in regulating appetite, growth hormone secretion, and gastrointestinal motility. RQ-00433412 is being developed for the treatment of constipation and cancer-related anorexia/cachexia syndrome. In cancer patients, it is intended to improve quality of life by addressing cachexia and weight loss, while in patients with constipation, it aims to promote spontaneous bowel movement through its gastrointestinal prokinetic effects without the common side effect of diarrhea. As of current development reports, RaQualia Pharma has completed preclinical studies and is actively seeking out-licensing partners to advance the candidate into clinical trials.